SCM
PVLA

Suvretta Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Suvretta Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174M Sell
1,135,406
-18,090
-2% -$2.2M 3.17% 5
2026
Q1 		$144M Buy
1,153,496
+261,096
+29% +$27.2M 3.67% 4
2025
Q4 		$93.4M Buy
892,400
+70,000
+9% +$5.97M 1.91% 16
2025
Q3 		$51.6M Buy
822,400
+107,937
+15% +$4.81M 1.32% 27
2025
Q2 		$16.1M Hold
714,463
– – 0.49% 48
2025
Q1 		$20M Hold
714,463
– – 0.74% 38
2024
Q4 		$8.57M Buy
+714,463
New +$11.2M 0.29% 58

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Suvretta Capital Management's PVLA Position: Q2 2026 in Review

Suvretta Capital Management reduced its Palvella Therapeutics (PVLA) stake by 1.6% in Q2 2026, selling an estimated $2.2M and leaving 1,135,406 shares worth $174M. The position accounts for 3.17% of the portfolio, ranked #5.

Suvretta Capital Management first reported a position in PVLA in Q4 2024 and has held it in 7 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Suvretta Capital Management held 1,135,406 shares of Palvella Therapeutics worth $174M as of Q2 2026.
  • Suvretta Capital Management sold 18,090 Palvella Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Palvella Therapeutics made up 3.17% of Suvretta Capital Management's portfolio in Q2 2026, its #5 holding.
  • Suvretta Capital Management first reported a position in Palvella Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.